Scopolamine Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Scopolamine Market is Segmented By Dosage form (Tablets, Syrups, Patches, Injections, Others), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Scopolamine Market Overview

The Scopolamine Market report analyzes the global market size, shares, recent trends, competitive intelligence, and future market outlook. Scopolamine is a medication used to prevent nausea, vomiting, and motion sickness. It belongs to the anticholinergic class of drugs and is commonly available as a transdermal patch. The market is driven by factors such as the increasing prevalence of motion sickness and the growing demand for effective antiemetic medications. In the Asia Pacific region, the Scopolamine Market is witnessing significant growth. Key players in the market include Novartis AG, Baxter International Inc., Pfizer Inc., and other prominent players operating in the market.

Scopolamine, commonly known as hyoscine or devil's breath, is a tropane alkaloid and anticholinergic medication that is naturally or synthetically manufactured. It is formally used to treat motion sickness and postoperative nausea and vomiting. Scopolamine may also treat stomach or intestine issues such as spastic muscular states, diverticulitis, irritable bowel syndrome, and Parkinson-like symptoms.

Scopolamine Market Scope

For more insights - Download the Sample

Scopolamine Market Dynamics

Major factors driving the global scopolamine market are food habits and casual lifestyles, which affect the digestive system as well as the gastrointestinal system; scopolamine is used to treat acute vertigo, increase the prevalence of dizziness, also helps in market growth, and even psychological stress is considered to one of the significant contributors to motion sickness.

The increasing prevalence of cancer worldwide is expected to drive market growth.

According to the WHO statistics, cancer accounted for ten million deaths in the year 2020, about 1 in 6 deaths from cancer. Out of which, around 70% of deaths occurred in low- and middle-income countries; the most common types of cancer are breast (2.26 million cases in 2020), lung (around 2.21 million cases in 2020), and colon & rectum cancers (1.93 million cases in 2020). Therefore, it has led to an increase in chemotherapy, which led to the demand for scopolamine drugs. Thus, from the above factors, the market is expected to drive market growth in the forecast period.

Side effects and product discontinuation of scopolamine drugs are expected to hamper market growth.

However, the side effects of scopolamine and product discontinuation by certain market players hamper the global scopolamine market growth during the forecast period. For instance, scopolamine has common as Agitation, less common side effects such as dilated, bigger, or enlarged pupils (black part of the eye), blurred vision or other changes in vision, confusion, and increased sensitivity of the eyes to light. Furthermore, Perrigo has discontinued the scopolamine transdermal system due to business reasons, thus, slowing the global scopolamine market growth during the forecast.

COVID-19 Impact on Scopolamine Market Growth

The ongoing COVID-19 pandemic has negatively impacted the worldwide scopolamine market, owing to a decline in the number of surgical operations resulting from chronic conditions. For instance, according to the National Center for Biotechnology Information statistics in May 2020, the surgical practice was greatly impacted by all special rules to manage the crisis. The pandemic impacted working methods, surgical procedures, minimally invasive surgery, theatre workflow, patient and staff safety, training, and education. In contrast, surgical teams were encouraged to offer phone or video consultations wherever possible and cancel non-essential follow-ups to reduce patient interaction. As a result, the number of surgery procedures was reduced, as was the necessity for the scopolamine transdermal patch, which was used to prevent nausea and vomiting following anesthesia, narcotic pain medications, and surgery.

Scopolamine Market Segmentation Analysis

The transdermal patches segment is expected to hold the largest market share in scopolamine

The transdermal patches segment accounted for the largest market share in 2021. The segment benefits because they are preferred for their ease of use, low cost, and availability. The patch is placed behind the ear on the hairless skin and is used to relieve motion sickness caused by anesthetic during surgery. Furthermore, transdermal scopolamine can be eliminated from the body when it is no longer needed. For instance, Novartis AG, Transderm Scop (scopolamine) TRANSDERMAL SYSTEM 1.5 mg is a prescription drug used to treat the symptoms of vomiting caused by motion sickness from anesthesia. Therefore, it has increased the demand for scopolamine transdermal patches. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.

Scopolamine Market Geographical Share

North America region holds the largest market share in the global scopolamine  

North America region is accounted for the largest market share in 2021. The increasing prevalence of cancer-related surgeries, rising awareness of transdermal scopolamine patches among people, product launches and acquisition and collaborations of market players and FDA approvals in the region are the factors drive the market in the period. For instance, according to the National Cancer Institute, in 2020, 1,806,590 new cases were diagnosed, with 606,520 deaths registered of cancer. In addition, in 2021, around 1.9 million were diagnosed, and 608,570 deaths were confirmed of cancer, as per the American Cancer Society. According to the projection by CDC, new cancer cases per year will rise to 29.5 million by 2040. Besides, cancer-related surgeries have also increased with the increasing demand for scopolamine drugs to treat nausea and vomiting.

Moreover, Ingenus Pharmaceuticals, LLC (Riconpharma LLC.) received approval from the United States Food and Drug Administration in December 2021 to manufacture the generic variant of Transderm-Scop (skin patch). As a result, such advancements tend to boost the region's studied market. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.

Scopolamine Market Companies and Competitive Landscape

Major key players in the scopolamine market are Baxter International Inc., GlaxoSmithKline plc., Novartis AG, Perrigo Company plc., Caleb Pharmaceuticals, Inc., Myungmoon Pharma Co. LTD., Alchem International, Phytex Australia, Centroflora-Cms, Alkaloids of Australia and Fine Chemical Corporation.

On March 2, 2022, Athira Pharma, Inc. used scopolamine, a novel small molecule candidate for Parkinson's disease dementia, Alzheimer's, and Dementia with Lewy bodies, and ATH-1020, an orally accessible, brain-penetrant small molecule candidate for neuropsychiatric diseases.

Novartis AG:

Overview:

Novartis AG is a multinational pharmaceutical company based out of Switzerland. The company engages in developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develop, manufactures, distributes and sells patented pharmaceuticals and comprises two business units: Novartis Oncology and Novartis Pharmaceuticals. Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments. The Sandoz segment develops, manufactures and markets finished dosage form medicines and intermediary products, including active pharmaceutical ingredients.

­Product Portfolio:

Transderm Scop (scopolamine) TRANSDERMAL SYSTEM 1.5 mg: Transderm Scop is a prescription medicine used to treat the symptoms of nausea or vomiting caused by motion sickness or from anesthesia.

The global scopolamine report would provide an access to an approx. 45+market data table, 40+figures and 180pages